AYTU - Aytu BioScience Inc Stock Price, Fair Value and News

2.94USD-0.02 (-0.68%)Delayed

Market Summary

USD2.94-0.02

Delayed

-0.68%

AYTU Stock Price

View Fullscreen

AYTU RSI Chart

AYTU Valuation

Market Cap

16.4M

Price/Earnings (Trailing)

-1.2

Price/Sales (Trailing)

0.17

EV/EBITDA

65.95

Price/Free Cashflow

1.87

AYTU Price/Sales (Trailing)

AYTU Profitability

Operating Margin

56.05%

EBT Margin

-13.45%

Return on Equity

-44.46%

Return on Assets

-10.62%

Free Cashflow Yield

53.54%

AYTU Fundamentals

AYTU Revenue

Revenue (TTM)

93.8M

Rev. Growth (Yr)

-20.85%

Rev. Growth (Qtr)

-21.54%

AYTU Earnings

Earnings (TTM)

-13.7M

Earnings Growth (Yr)

59.9%

Earnings Growth (Qtr)

-1.2K%

Breaking Down AYTU Revenue

Last 7 days

-10.1%

Last 30 days

2.4%

Last 90 days

-7.3%

Trailing 12 Months

53.9%

How does AYTU drawdown profile look like?

AYTU Financial Health

Current Ratio

0.85

AYTU Investor Care

Shares Dilution (1Y)

47.30%

Diluted EPS (TTM)

-6.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	93.8M	0	0	0
2023	104.1M	107.4M	101.8M	98.5M
2022	92.7M	96.7M	102.4M	105.6M
2021	57.0M	65.6M	74.0M	82.0M
2020	14.5M	27.6M	39.7M	51.7M
2019	6.5M	7.3M	7.3M	8.7M
2018	3.6M	3.7M	4.0M	4.8M
2017	3.3M	3.3M	3.3M	3.4M
2016	1.8M	2.6M	2.8M	3.1M
2015	110.2K	261.8K	721.6K	1.2M
2014	31.7K	45.3K	76.7K	92.5K
2013	33.6K	41.8K	18.1K	0
2012	0	0	17.2K	25.4K
2011	0	0	0	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aytu BioScience Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	pyszczymuka greg	acquired	-	-	208	chief commercial officer
Dec 31, 2023	pyszczymuka greg	acquired	-	-	209	chief commercial officer
Sep 30, 2023	pyszczymuka greg	acquired	-	-	208	chief commercial officer
Aug 16, 2023	jain abhinav	acquired	-	-	6,500	-
Aug 11, 2023	liu vivian h	acquired	-	-	1,500	-
Aug 11, 2023	jain abhinav	acquired	-	-	1,500	-
Aug 11, 2023	dockery carl	acquired	-	-	1,500	-
Aug 11, 2023	donofrio john jr.	acquired	-	-	1,500	-
Jun 30, 2023	pyszczymuka greg	acquired	-	-	208	chief commerical officer
Jun 16, 2023	pyszczymuka greg	bought	22,428	1.869	12,000	chief commerical officer

Which funds bought or sold AYTU recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	reduced	-24.29	-753	3,222	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	37,012	37,012	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	unchanged	-	2,776	42,201	-%
May 15, 2024	Royal Bank of Canada	reduced	-24.73	-2,000	8,000	-%
May 15, 2024	Stonepine Capital Management, LLC	unchanged	-	94,494	1,436,310	1.14%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-50.00	-2,869,180	3,303,910	0.19%
May 15, 2024	Tower Research Capital LLC (TRC)	added	32.54	2,715	9,199	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	152	152	-%
May 14, 2024	NORTHERN TRUST CORP	reduced	-0.03	2,902	44,275	-%
May 14, 2024	NewEdge Advisors, LLC	unchanged	-	4.00	64.00	-%

Are Funds Buying or Selling AYTU?

Are funds buying AYTU calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AYTU

No. of Funds

Unveiling Aytu BioScience Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	stonepine capital management, llc	9.99%	565,484	SC 13G/A
Jun 16, 2023	stonepine capital management, llc	9.99%	563,842	SC 13G
Jun 16, 2023	nantahala capital management, llc	19.7%	1,086,812	SC 13D/A
May 26, 2023	nantahala capital management, llc	7.2%	271,595	SC 13D
Feb 14, 2023	cvi investments, inc.	4.9%	3,278,844	SC 13G/A
Aug 15, 2022	cvi investments, inc.	5.6%	3,400,000	SC 13G
Feb 11, 2022	stonepine capital management, llc	0%	0	SC 13G/A
Sep 01, 2021	armistice capital, llc	4.9%	-	SC 13D/A
Aug 31, 2021	armistice capital, llc	5.3%	-	SC 13D/A
Mar 26, 2021	integrated core strategies (us) llc	0.0%	2,446	SC 13G

Recent SEC filings of Aytu BioScience Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
May 10, 2024	DEFA14A	DEFA14A
May 10, 2024	DEF 14A	DEF 14A
May 10, 2024	ARS	ARS
Apr 02, 2024	4	Insider Trading
Feb 14, 2024	8-K	Current Report
Feb 14, 2024	10-Q	Quarterly Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Aytu BioScience Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Aytu BioScience Inc News

Latest updates

Aytu BioScience Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-21.5%	17,993	22,934	22,099	30,732	22,733	26,279	27,655	27,448	24,199	23,125	21,897	23,482	13,483	15,147	13,520	14,861	8,156	3,175	1,440	1,716	2,378
Cost Of Revenue	-	-	-	-	-	9,990	8,986	9,623	12,606	11,513	10,826	9,441	12,183	13,935	6,251	4,063	5,301	1,999	606	376	649	617
Gross Profit	-27.8%	11,693	16,203	14,784	18,564	12,743	17,293	18,032	14,842	12,686	12,299	12,456	11,299	-452	8,896	9,457	-	-	-	-	-	-
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	39,148	20,722	-	-	12,950	8,142	-	-	-
Operating Expenses	2.3%	14,157	13,839	16,288	18,395	21,301	24,161	19,840	32,058	66,107	23,593	40,155	35,371	25,214	14,471	13,014	13,215	12,950	8,142	6,175	6,296	6,676
S&GA Expenses	-0.4%	6,549	6,576	7,422	7,982	12,804	10,560	10,102	10,013	9,743	9,660	9,297	12,180	6,597	5,705	5,826	-8,770	9,190	6,516	5,146	4,896	5,369
R&D Expenses	18.1%	619	524	604	465	856	1,710	1,064	3,253	3,282	4,475	1,652	4,764	390	286	183	1,499	79.00	67.00	78.00	175	109
EBITDA Margin	98.8%	0.00*	-0.05*	-0.11*	-0.04*	-0.18*	-0.61*	-0.68*	-0.99*	-1.04*	-0.85*	-0.93*	-0.72*	-0.09*	-	-	-	-	-	-	-	-
Interest Expenses	22.6%	994	811	1,359	951	840	1,456	565	68.00	724	668	1,688	800	142	59.00	248	253	539	447	195	137	195
Income Taxes	-70.4%	245	828	-	-	-	-	-	-	-	-3.00	-107	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-534.5%	-2,642	608	-8,120	-2,457	-7,200	-6,693	-701	-16,089	-53,291	-11,551	-27,958	-18,739	-25,460	-9,525	-4,306	-	-	-	-	-	-
EBT Margin	22.8%	-0.13*	-0.17*	-0.24*	-0.16*	-0.29*	-0.73*	-0.80*	-1.13*	-1.20*	-1.02*	-1.10*	-0.88*	-0.24*	-	-	-	-	-	-	-	-
Net Income	-1212.3%	-2,887	-220	-8,120	-2,457	-7,200	-6,693	-701	-16,089	-53,291	-11,548	-27,851	-18,998	-25,460	-9,525	-4,306	-3,145	-5,332	-214	-4,929	-14,531	-4,495
Net Income Margin	20.1%	-0.15*	-0.18*	-0.24*	-0.16*	-0.29*	-0.73*	-0.80*	-1.13*	-1.20*	-1.02*	-1.11*	-0.89*	-0.74*	-	-	-	-	-	-	-	-
Free Cashflow	-2.1%	5,596	5,715	5,639	15,215	2,956	3,398	-3,298	-1,222	-3,265	-2,972	2,059	-427	25,550	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.8%	129	131	133	136	147	141	150	138	169	224	228	266	272	167	141	153	159	74.00	31.00	35.00	38.00
Current Assets	-0.3%	71.00	71.00	71.00	73.00	78.00	71.00	74.00	60.00	78.00	88.00	89.00	105	100	93.00	65.00	75.00	83.00	18.00	12.00	15.00	18.00
Cash Equivalents	1.4%	20.00	20.00	20.00	23.00	19.00	20.00	24.00	19.00	28.00	35.00	40.00	50.00	47.00	62.00	38.00	48.00	62.00	5.00	7.00	11.00	15.00
Inventory	1.5%	13.00	13.00	13.00	12.00	14.00	13.00	13.00	11.00	14.00	17.00	16.00	16.00	17.00	7.00	11.00	10.00	4.00	2.00	1.00	1.00	2.00
Net PPE	-14.2%	1.00	1.00	-	2.00	-	-	-	-	-	-	-	-	6.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	-	-	-	-	-	-	-	-	-	9.00	46.00	46.00	66.00	38.00	28.00	28.00	28.00	24.00	15.00	-	-	-
Liabilities	-	-	-	101	97.00	106	96.00	102	93.00	108	118	116	128	128	54.00	50.00	58.00	73.00	57.00	29.00	28.00	22.00
Current Liabilities	30.4%	84.00	64.00	65.00	69.00	85.00	67.00	73.00	64.00	80.00	101	98.00	109	84.00	26.00	22.00	29.00	42.00	16.00	6.00	5.00	5.00
Short Term Borrowings	54.1%	2.00	1.00	1.00	2.00	10.00	7.00	-	4.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	-100.0%	-	15.00	15.00	15.00	11.00	15.00	14.00	14.00	14.00	0.00	0.00	0.00	-	-	-	-	8.00	23.00	-	-	5.00
LT Debt, Current	38707.7%	15.00	0.00	-	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	15.00	-	15.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-6.3%	31.00	33.00	32.00	39.00	41.00	46.00	48.00	44.00	58.00	106	112	138	143	113	91.00	95.00	86.00	17.00	2.00	7.00	16.00
Retained Earnings	-0.9%	-315	-312	-312	-304	-301	-294	-287	-287	-270	-217	-206	-178	-159	-133	-124	-120	-116	-111	-111	-106	-91.86
Additional Paid-In Capital	0.2%	346	345	344	343	343	340	336	331	329	323	318	316	302	247	215	215	203	129	114	113	108
Shares Outstanding	0.0%	6.00	6.00	6.00	6.00	4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	12.00	-	-	-	38.00	-	-	-	88.00	-	-	-	10.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-88.1%	-254	-135	-211	9,365	-2,894	-2,452	-9,148	-7,072	-9,115	-8,822	-3,791	-6,277	19,700	-2,917	-7,983	-7,764	20,600	-6,099	-2,987	-3,473	-3,310
Share Based Compensation	-1.1%	811	820	930	900	902	3,067	1,177	1,230	1,270	1,229	1,519	1,089	1,522	508	455	488	263	162	165	299	377
Cashflow From Investing	74.1%	-45.00	-174	-76.00	-155	1.00	-5.00	42.00	-41.00	-70.00	-3,051	-86.00	-2,426	-317	-30.00	-9.00	-45.27	344	-4,912	-1,042	-96.11	-105
Cashflow From Financing	520.6%	530	-126	-2,734	-5,404	2,583	-1,865	13,557	-1,117	1,521	6,590	-5,464	11,814	-6,398	27,076	-2,178	-6,372	68,183	9,258	-	117	259

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AYTU Income Statement

2024-03-31

Unaudited Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Net revenue	$ 17,993	$ 22,733	$ 63,026	$ 76,667
Cost of sales	6,300	9,990	20,346	28,599
Gross profit	11,693	12,743	42,680	48,068
Operating expenses:
Selling and marketing	6,549	12,804	20,547	33,466
General and administrative	5,442	7,177	17,837	22,517
Research and development	619	856	1,747	3,630
Amortization of intangible assets	1,303	1,198	3,909	3,593
Restructuring costs	244	0	244	0
Impairment expense	0	0	0	2,600
Gain from contingent consideration	0	(734)	0	(504)
Total operating expenses	14,157	21,301	44,284	65,302
Loss from operations	(2,464)	(8,558)	(1,604)	(17,234)
Other expense, net	(1,195)	(1,215)	(3,083)	(3,527)
Gain (loss) on derivative warrant liabilities	1,017	2,573	(5,467)	6,167
Loss before income tax	(2,642)	(7,200)	(10,154)	(14,594)
Income tax expense	(245)	0	(1,073)	0
Net loss	$ (2,887)	$ (7,200)	$ (11,227)	$ (14,594)
Basic and diluted weighted-average common shares outstanding (in shares)	5,533,555	3,726,779	5,511,089	3,099,130
Basic and diluted net loss per common share (in dollars per share)	$ (0.52)	$ (1.93)	$ (2.04)	$ (4.71)

AYTU Balance Sheet

2024-03-31

Unaudited Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 19,760	$ 22,985
Accounts receivable, net	29,925	28,937
Inventories	13,193	11,995
Prepaid expenses	7,249	8,047
Other current assets	1,003	868
Total current assets	71,130	72,832
Non-current assets:
Property and equipment, net	967	1,815
Operating lease right-of-use assets	1,795	2,054
Intangible assets, net	54,082	58,970
Other non-current assets	889	792
Total non-current assets	57,733	63,631
Total assets	128,863	136,463
Current liabilities:
Accounts payable	10,475	13,478
Accrued liabilities	44,091	46,799
Short-term line of credit	1,581	1,563
Current portion of debt	15,135	85
Current portion of derivative warrant liabilities	3,261	0
Other current liabilities	9,146	7,090
Total current liabilities	83,689	69,015
Non-current liabilities:
Debt, net of current portion	0	14,713
Derivative warrant liabilities	8,609	6,403
Other non-current liabilities	5,788	6,975
Total non-current liabilities	14,397	28,091
Commitments and contingencies (note 13)
Stockholders’ equity:
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, par value $.0001; 200,000,000 shares authorized; 5,567,909 and 5,517,174 shares issued and outstanding, respectively	1	1
Additional paid-in capital	346,132	343,485
Accumulated deficit	(315,356)	(304,129)
Total stockholders’ equity	30,777	39,357
Total liabilities and stockholders’ equity	$ 128,863	$ 136,463

About Aytu BioScience Inc

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment, which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. In addition, the company provides Karbinal ER, for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

CEO	Mr. Joshua R. Disbrow
WEBSITE	https://aytubio.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	164

Aytu BioScience Inc Frequently Asked Questions

What is the ticker symbol for Aytu BioScience Inc? What does AYTU stand for in stocks?

AYTU is the stock ticker symbol of Aytu BioScience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aytu BioScience Inc (AYTU)?

As of Fri May 17 2024, market cap of Aytu BioScience Inc is 16.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AYTU stock?

You can check AYTU's fair value in chart for subscribers.

What is the fair value of AYTU stock?

You can check AYTU's fair value in chart for subscribers. The fair value of Aytu BioScience Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aytu BioScience Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AYTU so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aytu BioScience Inc a good stock to buy?

The fair value guage provides a quick view whether AYTU is over valued or under valued. Whether Aytu BioScience Inc is cheap or expensive depends on the assumptions which impact Aytu BioScience Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AYTU.

What is Aytu BioScience Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AYTU's PE ratio (Price to Earnings) is -1.2 and Price to Sales (PS) ratio is 0.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AYTU PE ratio will change depending on the future growth rate expectations of investors.